← ANALYST RATINGS · TIPRANKS
Supernus Pharmaceuticals (SUPN): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy0 Hold0 Sell
Ratings of 1 analysts in the last 3 months · top analysts only12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $66.00, the highest $66.00, the lowest $66.00. The average is +74.2% from the last price of $37.88.
Analyst ratings 8
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $45.00 → $41.00−8.9% | Hold | +8.2% | Reiterated | 16.10.26on TipRanks 08:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $45.00 → $41.00−8.9% | Hold | +8.2% | Reiterated | 16.10.26on TipRanks 08:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $44.00 → $41.00−6.8% | Hold | +8.2% | Reiterated | 16.10.26on TipRanks 08:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $44.00 → $40.00−9.1% | Hold | +5.6% | Reiterated | 16.10.26on TipRanks 08:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $43.00 → $39.00−9.3% | Hold | +3.0% | Reiterated | 16.10.26on TipRanks 08:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $44.00 → $40.00−9.1% | Hold | +5.6% | Reiterated | 16.10.26on TipRanks 08:05 | — | |
| Chi Meng Fong★★★★★★★★★★#8521 · hits 44% · avg +0.2% | Bank of America Securities | $60.00 → $55.00−8.3% | Buy | +45.2% | Reiterated | 15.10.26on TipRanks 06:10 | −1.8%next day −3.2% | ↗ |
| Chi Meng Fong★★★★★★★★★★#8521 · hits 44% · avg +0.2% | Bank of America Securities | $60.00 | Buy | +58.4% | Reiterated | 12.10.26on TipRanks 08:15 | +0.4%next day −1.9% | ↗ |
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $51.00 → $45.00−11.8% | Hold | +18.8% | Reiterated | 07.09.26on TipRanks 00:06 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $51.00 → $45.00−11.8% | Hold | +18.8% | Reiterated | 07.09.26on TipRanks 00:06 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $51.00 → $44.00−13.7% | Hold | +16.2% | Reiterated | 07.09.26on TipRanks 00:06 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $49.00 → $44.00−10.2% | Hold | +16.2% | Reiterated | 07.09.26on TipRanks 00:06 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $50.00 → $43.00−14.0% | Hold | +13.5% | Reiterated | 07.09.26on TipRanks 00:06 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $52.00 → $44.00−15.4% | Hold | +16.2% | Reiterated | 07.09.26on TipRanks 00:06 | — | |
| Stacy Ku★★★★★★★★★★#2387 · hits 50% · avg +9.3% | TD Cowen | $65.00 | Buy | +71.6% | Reiterated | 03.08.26on TipRanks Aug 4 01:20 | +1.6%next day −7.8% · 5 days +0.3% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $66.00 | Buy | +74.2% | Reiterated | 27.07.26on TipRanks 10:19 | +1.7%next day +1.4% · 5 days −4.6% | ↗ |
| Chi Meng Fong★★★★★★★★★★#8521 · hits 44% · avg +0.2% | Bank of America Securities | $63.00 | Buy | +66.3% | Reiterated | 13.07.26on TipRanks 06:10 | −1.5%next day −1.8% · 5 days +1.1% | ↗ |
| Unknown Analyst | Jefferies | $65.00 | Buy | +71.6% | Reiterated | 10.07.26on TipRanks Jul 13 06:10 | −1.0%next day −1.5% · 5 days +0.7% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $63.00 → $67.00+6.3% | Buy | +76.9% | Reiterated | 09.07.26on TipRanks 08:21 | −4.2%next day −1.0% · 5 days −1.0% | ↗ |
| Annabel Samimy★★★★★★★★★★#421 · hits 51% · avg +19.3% | Stifel Nicolaus | $55.00 | Hold | +45.2% | Reiterated | 06.05.26on TipRanks 11:35 | +3.2%next day +1.9% · 5 days −1.3% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Supernus Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $65.20 at a price of $43.04 (+51.5%); now: $62.00 at $37.88 (+63.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 4 | 4 | 3 | 2 | 0 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.56 (from $0.49 to $0.62). Last quarter: $0.53.
Sales
Next quarter’s sales estimate — $219M (from $211M to $224M). Last quarter: $219M.
Best top-analyst consensus in the sector · Healthcare
About Supernus Pharmaceuticals
- CEO: Jack A. Khattar
- Employees: 778
- 9715 Key West Avenue, Rockville, MD, 20850, US
- www.supernus.com
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Data from the stock’s TipRanks forecast page, read 134 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗